Peptide 101: Ipamorelin Acetate

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that selectively stimulates GH release from the pituitary gland. It is considered the most selective GHRP, producing robust GH release with minimal impact on cortisol, prolactin, and appetite — making it the cleanest GH secretagogue in its class. It is one of the most widely prescribed peptides in anti-aging and optimization clinics.

Older growth-hormone peptides like GHRP-6 act like a stereo's master volume—turn it up and everything gets louder together: growth hormone, yes, but also your appetite and your stress hormone, cortisol. Ipamorelin behaves more like an equalizer. It slides up only the growth-hormone channel and leaves appetite and stress hormones right where they belong. It also works with your body's natural rhythm instead of overriding it, releasing growth hormone in the same steady on-and-off pulses your body already makes on its own—mostly while you sleep.

For the nerds:

Ipamorelin is a selective growth hormone secretagogue that binds the ghrelin receptor (GHS-R1a) on pituitary somatotrophs, driving GH release in a pulsatile pattern that mirrors physiologic secretion rather than clamping it high. Its defining advantage over GHRP-2 and GHRP-6 is selectivity: at therapeutic doses it produces minimal ACTH/cortisol or prolactin stimulation, yielding a markedly cleaner endocrine profile and avoiding the appetite spike and HPA-axis noise those older peptides carry. It's mechanistically complementary to GHRH analogs like CJC-1295—the GHRH analog initiates and widens the GH pulse while ipamorelin amplifies pulse amplitude, and because both act upstream on the pituitary rather than replacing GH directly, the GH/IGF-1 feedback loop and its somatostatin "off switch" stay intact. That preserved feedback ceiling is the core reason a secretagogue approach carries a different (generally more favorable) safety profile than exogenous rhGH.

Overall strength of the evidence, by our read: Theoretical. Some of what that rests on:

Preliminary or early findings are not the same as proof. Any use beyond a peptide's FDA-approved labeling (where one exists) is described here for educational purposes only and is not a recommendation.

Ipamorelin is generally well tolerated with a favorable side effect profile compared to other GH secretagogues. Reported side effects include mild headache, transient flushing, edema, and injection site irritation. It does not significantly increase appetite, cortisol, or prolactin at standard doses. Long-term safety data from large controlled trials is limited.

Reasons to avoid it, or to talk to a clinician first:

This is not a complete safety list.

2026-09-01 · INTERVENTIONAL · melatonin

Researchers at Rutgers are running a small study to see whether melatonin—the natural sleep hormone your body makes—can help critically ill patients in the ICU sleep better, since hospital intensive-care units are noisy, bright places where real rest is hard to get. Each patient will wear a soft headband that tracks their brain waves during sleep, then take a 3 mg dose of melatonin, and researchers will measure how well and how deeply they sleep. This is an early pilot study of just 30 people that hasn't started yet, so there are no results to report—it's simply checking whether melatonin improves sleep quality in this setting.

Source ↗

2026-08-28 · INTERVENTIONAL · tirzepatide

Doctors at the Cleveland Clinic are starting a study to see if tirzepatide—the same medicine many people use for weight loss and blood sugar—can help people with COPD, a serious lung disease that also weakens muscles and causes body-wide inflammation. They'll give the medicine to overweight adults with COPD for one year and carefully measure their breathing, muscle strength, walking ability, and inflammation to see if it helps the lungs and body, not just the waistline. This is a small early study of 30 people that's just beginning and won't finish until 2029, so there are no results yet—it's testing a promising idea, not proof that it works.

Source ↗

Topics we'll be tracking:

About Ipamorelin

Ipamorelin has NOT been approved by the U.S. Food and Drug Administration for any medical use. This substance was previously on the FDA's Category 2 restricted list but the nominator withdrew. Its compounding status is legally ambiguous — it is neither explicitly prohibited nor explicitly authorized under current FDA interim policy. Compounded versions of Ipamorelin are NOT the same as FDA-approved products. Compounded drugs have not undergone FDA review for safety, efficacy, or manufacturing quality. The FDA has warned that compounded versions may contain different salt forms, concentrations, or impurities. Discuss the risks and regulatory status of compounded medications with your prescriber. NOTE: A policy announcement regarding potential reclassification of this substance was made in February 2026. However, as of the date of this content, no formal FDA rule change has been published in the Federal Register. The current regulatory status described above remains in effect until a formal rule is finalized.

Medical disclaimer

This letter is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment, and no provider-patient relationship is created by reading it. Peptides and medications discussed may not be FDA-approved for the uses described. Always consult your healthcare provider before making any health decision. Read our full medical disclaimer.